Published in AIDS Weekly, November 18th, 2002
"Third quarter revenue increased 8.6%, driven primarily by strong activity in two service contracts related to HIV vaccine development and hepatitis C," said Kevin W. Quinlan, Boston Biomedica, Inc. "This was partially offset by disappointing product revenue, caused primarily by postponed and cancelled orders as the current economic downturn in the IVD industry hurt our customers' test kit sales and new test development. The result was an unfavorable mix shift that adversely impacted gross margin and operating performance.
"Nonetheless we remain encouraged as we...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.